Jumamyradov Maksat, Craig Benjamin M
Department of Economics, University of South Florida, Tampa, FL, USA.
Department of Health Outcomes Research and Policy, Auburn University, Auburn, AL, USA.
Pharmacoeconomics. 2025 Feb;43(2):171-176. doi: 10.1007/s40273-024-01444-1. Epub 2024 Nov 2.
A key challenge in value assessment is how to summarize effectiveness, particularly the impact of interventions on patient health-related quality of life (HRQoL). One approach is to quantify the gains in HRQoL and life expectancy together as quality-adjusted life years (QALYs); however, this approach has faced various criticisms regarding its potential discriminatory aspects toward persons with disabilities, older adults, and the most vulnerable individuals in society.
Instead of QALYs, we provide an alternative approach that summarizes HRQoL gains from the perspective of its stakeholders (e.g., patients, parents, and caregivers) using an "experience" scale. On an experience scale, a positive value signifies an experience better than having no experience at all, while a negative value indicates an experience worse than having no experience. To illustrate the merits of this approach, we examine US preferences on the relief of child health problems, namely a discrete choice experiment (DCE) with kaizen tasks and alternatives described using the EQ-5D-Y-3L.
Using this approach, we demonstrate the differences in perspectives between parents (N = 179), mothers (N = 99), and fathers (N = 80) of children younger than 18 years of age, as well as the feasibility of this patient-centered approach using a brief DCE survey of less than 100 respondents each (and without QALYs). Specifically, we found that mothers place a higher value on the child's feelings than fathers. The results also suggest other differences between the perspectives of mothers and fathers, but these differences were not statistically significant (p-values < .05).
We put forth that future value assessments may summarize gains in HRQoL on a patient experience scale (i.e., experience scale from the patient perspective) to inform decision-making.
价值评估中的一个关键挑战是如何总结有效性,特别是干预措施对患者健康相关生活质量(HRQoL)的影响。一种方法是将HRQoL和预期寿命的增加量一起量化为质量调整生命年(QALYs);然而,这种方法因其对残疾人、老年人和社会中最弱势群体可能存在的歧视性方面而面临各种批评。
我们提供了一种替代QALYs的方法,该方法使用“体验”量表从利益相关者(如患者、父母和护理人员)的角度总结HRQoL的改善情况。在体验量表上,正值表示体验优于完全没有体验,而负值表示体验比没有体验更差。为了说明这种方法的优点,我们研究了美国对儿童健康问题缓解的偏好,即一项使用EQ-5D-Y-3L描述改善任务和替代方案的离散选择实验(DCE)。
使用这种方法,我们展示了18岁以下儿童的父母(N = 179)、母亲(N = 99)和父亲(N = 80)之间观点的差异,以及使用每项调查对象少于100人的简短DCE调查(且不使用QALYs)的这种以患者为中心的方法的可行性。具体而言,我们发现母亲比父亲更看重孩子的感受。结果还表明了母亲和父亲观点之间的其他差异,但这些差异无统计学意义(p值 <.05)。
我们提出,未来的价值评估可以在患者体验量表(即从患者角度的体验量表)上总结HRQoL的改善情况,以为决策提供信息。